BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 9678115)

  • 1. The effects of a low-dose gestodene-containing oral contraceptive on endometrial histology in healthy women.
    Coenen CM; Hollanders JM; Rolland R; Spielmann D; Bulten J
    Eur J Contracept Reprod Health Care; 1996 Dec; 1(4):325-9. PubMed ID: 9678115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and acceptability of two monophasic oral contraceptives containing ethinylestradiol and either desogestrel or gestodene.
    Halbe HW; de Melo NR; Bahamondes L; Petracco A; Lemgruber M; de Andrade RP; da Cunha DC; Guazelli CA; Baracat EC
    Eur J Contracept Reprod Health Care; 1998 Sep; 3(3):113-20. PubMed ID: 9853201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An open-label study of the effects of a 24-day regimen of gestodene 60 microg/ethinylestradiol 15 microg on endometrial histological findings in healthy women.
    Oosterbaan HP
    Eur J Contracept Reprod Health Care; 1999 Nov; 4 Suppl 2():3-8. PubMed ID: 14677619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 micrograms ethinylestradiol/75 micrograms gestodene and 30 micrograms ethinylestradiol/75 micrograms gestodene, with respect to efficacy, cycle control, and tolerance.
    Endrikat J; Müller U; Düsterberg B
    Contraception; 1997 Mar; 55(3):131-7. PubMed ID: 9115000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Body weight change during use of a monophasic oral contraceptive containing 20 microg ethinylestradiol and 75 microg gestodene with a comparison of the women who completed versus those who prematurely discontinued intake.
    Endrikat J; Gerlinger C; Cronin M; Wessel J; Ruebig A; Rosenbaum P; Düsterberg B
    Eur J Contracept Reprod Health Care; 2001 Dec; 6(4):199-204. PubMed ID: 11848649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparative study on the effects of a monophasic pill containing desogestrel plus 20 micrograms ethinylestradiol, a triphasic combination containing levonorgestrel and a monophasic combination containing gestodene on coagulatory factors.
    Melis GB; Fruzzetti F; Nicoletti I; Ricci C; Lammers P; Atsma WJ; Fioretti P
    Contraception; 1991 Jan; 43(1):23-31. PubMed ID: 1825970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparative randomized trial on the impact of two low-dose oral contraceptives on ovarian activity, cervical permeability, and endometrial receptivity.
    Rossmanith WG; Steffens D; Schramm G
    Contraception; 1997 Jul; 56(1):23-30. PubMed ID: 9306028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of two combined monophasic and triphasic ethinylestradiol/gestodene oral contraceptives on natural inhibitors and other hemostatic variables.
    Creatsas G; Kontopoulou-Griva I; Deligeoroglou E; Digenopoulou L; Tsangaris A; Kallipolitis G; Milingos S; Michalas S
    Eur J Contracept Reprod Health Care; 1997 Mar; 2(1):31-8. PubMed ID: 9678107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and desogestrel.
    Teichmann A
    Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():98-104. PubMed ID: 8574257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of two oral contraceptives containing ethinylestradiol and gestodene or norgestimate upon androgen parameters and serum binding proteins.
    Wiegratz I; Jung-Hoffmann C; Kuhl H
    Contraception; 1995 Jun; 51(6):341-6. PubMed ID: 7554973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect on blood pressure of a monophasic oral contraceptive containing ethinylestradiol and gestodene.
    Fuchs N; Düsterberg B; Weber-Diehl F; Mühe B
    Contraception; 1995 Jun; 51(6):335-9. PubMed ID: 7554972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of a new low-dose combined oral contraceptive containing levonorgestrel on ovarian activity.
    Teichmann A; Martens H; Bordasch C; Petersen G; Lorkowski G
    Eur J Contracept Reprod Health Care; 1996 Sep; 1(3):245-56. PubMed ID: 9678123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of gestodene and ethinylestradiol in 14 women during three months of treatment with a new tri-step combination oral contraceptive: serum protein binding of gestodene and influence of treatment on free and total testosterone levels in the serum.
    Kuhnz W; Baumann A; Staks T; Dibbelt L; Knuppen R; Jütting G
    Contraception; 1993 Oct; 48(4):303-22. PubMed ID: 8222659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A study of the influence of a gestodene-containing triphasic oral contraceptive on endometrial morphology.
    Rabe T; Leppien G; Fossman WG; Hessing C; Vladescú E; Runnebaum B
    Eur J Contracept Reprod Health Care; 1997 Sep; 2(3):193-201. PubMed ID: 9678092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New progestogens in oral contraceptives.
    Runnebaum B; Rabe T
    Am J Obstet Gynecol; 1987 Oct; 157(4 Pt 2):1059-63. PubMed ID: 2960242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of ovulation by an oral contraceptive containing 100 micrograms levonorgestrel in combination with 20 micrograms ethinylestradiol.
    Spona J; Feichtinger W; Kindermann C; Wünsch C; Brill K
    Contraception; 1996 Nov; 54(5):299-304. PubMed ID: 8934064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of follicular growth by two different oral contraceptives (monophasic and triphasic) containing ethinylestradiol and gestodene.
    Lete I; Morales P
    Eur J Contracept Reprod Health Care; 1997 Sep; 2(3):187-91. PubMed ID: 9678091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 micrograms ethinylestradiol/75 micrograms gestodene and 20 micrograms ethinylestradiol/150 micrograms desogestrel, with respect to efficacy, cycle control and tolerance.
    Endrikat J; Jaques MA; Mayerhofer M; Pelissier C; Müller U; Düsterberg B
    Contraception; 1995 Oct; 52(4):229-35. PubMed ID: 8605781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of gestodene and desogestrel as components of low-dose oral contraceptives on the pharmacokinetics of ethinyl estradiol (EE2), on serum CBG and on urinary cortisol and 6 beta-hydroxycortisol.
    Hammerstein J; Daume E; Simon A; Winkler UH; Schindler AE; Back DJ; Ward S; Neiss A
    Contraception; 1993 Mar; 47(3):263-81. PubMed ID: 8462317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative studies of 30 micrograms ethinyl estradiol combined with gestodene and desogestrel on blood coagulation, fibrinolysis, and platelets.
    Daly L; Bonnar J
    Am J Obstet Gynecol; 1990 Jul; 163(1 Pt 2):430-7. PubMed ID: 2142580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.